SCHEMBL4337647

SCHEMBL4337647

COc1c(NC(=O)c2cccs2)ccc2[nH]nc(-c3cc4ccccc4s3)c12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STK33 Q9BYT3 2/20 0.44
APLNR P35414 1/20 0.43
LMNA P02545 2/20 0.42
MAPT P10636 2/20 0.42
GAA P10253 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
RAB9A P51151 3/20 0.42
KDM4E B2RXH2 2/20 0.41
NPC1 O15118 2/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
POLB P06746 1/20 0.41
ALDH1A1 P00352 2/20 0.40
CACNA1B Q00975 1/20 0.40
APBA1 Q02410 1/20 0.40
TNIK Q9UKE5 1/20 0.40
TSHR P16473 1/20 0.40
MAPK10 P53779 1/20 0.40
MAPK14 Q16539 1/20 0.40
CYP1A2 P05177 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4329385 0.86 STK33 (0.44) STK33LMNAMAPTSMN1; SMN2RAB9A
SCHEMBL2867309 0.86 TNIK (0.44) LMNASMN1; SMN2RAB9AKDM4ENPC1
SCHEMBL2871502 0.85 SMN1; SMN2 (0.46) LMNAMAPTGAASMN1; SMN2RAB9A
SCHEMBL4338572 0.84 STK33 (0.47) STK33APLNRLMNAMAPTGAA
SCHEMBL4342242 0.83 HSD17B10 (0.43) LMNAMAPTSMN1; SMN2RAB9AKDM4E
SCHEMBL2867192 0.83 TNIK (0.41) MAPTSMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL4335786 0.82 MAPK10 (0.52) KDM4EALDH1A1TNIKMAPK10
SCHEMBL2865310 0.81 TNIK (0.40) MAPTSMN1; SMN2ALDH1A1TNIKMAPK10
SCHEMBL4334979 0.79 MAPT (0.44) LMNAMAPTGAASMN1; SMN2RAB9A
SCHEMBL4340656 0.79 MAPK10 (0.44) SMN1; SMN2MEN1KMT2ATNIKMAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
EP-1380576-B1 1H-INDAZOLE COMPOUNDS INHIBITING JNK EISAI R&D MAN CO LTD (JP) 2009-11-25 EP disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-7541376-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-02 US disclosed
US-20050282880-A1 Novel 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203691-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 STK33 118/4885APLNR 1938/4885LMNA 1893/4885
US-20050282880-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 STK33 118/4885APLNR 1938/4885LMNA 1893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.